163 related articles for article (PubMed ID: 37864678)
1. Efficacy of dotinurad in patients with severe renal dysfunction.
Kurihara O; Yamada T; Kato K; Miyauchi Y
Clin Exp Nephrol; 2024 Mar; 28(3):208-216. PubMed ID: 37864678
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis.
Yanai K; Hirai K; Kaneko S; Mutsuyoshi Y; Kitano T; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
Drug Des Devel Ther; 2023; 17():3233-3248. PubMed ID: 37941891
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Nephrol; 2021 Dec; 25(12):1336-1345. PubMed ID: 34328574
[TBL] [Abstract][Full Text] [Related]
4. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
Amano H; Kobayashi S; Terawaki H
BMC Nephrol; 2024 Mar; 25(1):97. PubMed ID: 38491453
[TBL] [Abstract][Full Text] [Related]
5. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
6. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
Fukase H; Okui D; Sasaki T; Fushimi M; Ohashi T; Hosoya T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):17-24. PubMed ID: 31823130
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m².
Mima A; Gotoda H; Lee S
Cureus; 2024 Mar; 16(3):e57362. PubMed ID: 38694413
[TBL] [Abstract][Full Text] [Related]
8. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
[No Abstract] [Full Text] [Related]
9. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Jeon HJ; Oh J; Shin DH
PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
[TBL] [Abstract][Full Text] [Related]
10. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M; Adachi H
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831103
[TBL] [Abstract][Full Text] [Related]
11. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
[TBL] [Abstract][Full Text] [Related]
14. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.
Kim Y; Shin S; Kim K; Choi S; Lee K
J Rheumatol; 2015 Nov; 42(11):2143-8. PubMed ID: 26428209
[TBL] [Abstract][Full Text] [Related]
15. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Ishikawa T; Takahashi T; Taniguchi T; Hosoya T
Expert Opin Pharmacother; 2021 Aug; 22(11):1397-1406. PubMed ID: 33926357
[TBL] [Abstract][Full Text] [Related]
16. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Levy G; Shi JM; Cheetham TC; Rashid N
Perm J; 2018; 22():17-142. PubMed ID: 30201087
[TBL] [Abstract][Full Text] [Related]
17. The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
Kuwabara Y; Yasuno S; Kasahara M; Ueshima K; Nakao K
Clin Exp Nephrol; 2020 May; 24(5):420-426. PubMed ID: 31875936
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Tanaka A; Taguchi I; Hisauchi I; Yoshida H; Shimabukuro M; Hongo H; Ishikawa T; Kadokami T; Yagi S; Sata M; Node K;
Eur J Med Res; 2023 Jul; 28(1):238. PubMed ID: 37461063
[TBL] [Abstract][Full Text] [Related]
19. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Okui D; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
[TBL] [Abstract][Full Text] [Related]
20. Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review.
Tsai CW; Lin SY; Kuo CC; Huang CC
PLoS One; 2017; 12(1):e0170393. PubMed ID: 28107415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
